Grifols SA ADR (GRFS)vsNovartis AG ADR (NVS)
GRFS
Grifols SA ADR
$7.71
+1.45%
HEALTHCARE · Cap: $7.65B
NVS
Novartis AG ADR
$150.75
+1.44%
HEALTHCARE · Cap: $286.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 654% more annual revenue ($56.67B vs $7.52B). NVS leads profitability with a 24.7% profit margin vs 5.0%. GRFS appears more attractively valued with a PEG of 0.23. GRFS earns a higher WallStSmart Score of 71/100 (B).
GRFS
Strong Buy71
out of 100
Grade: B
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$29.48
Current Price
$7.71
$21.77 discount
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$150.75
$102.13 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 20.4%
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Areas to Watch
4.0% revenue growth
ROE of 5.9% — below average capital efficiency
5.0% margin — thin
Elevated debt levels
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : GRFS
The strongest argument for GRFS centers on PEG Ratio, Price/Book, P/E Ratio. PEG of 0.23 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : GRFS
The primary concerns for GRFS are Revenue Growth, Return on Equity, Profit Margin. Debt-to-equity of 1.87 is elevated, increasing financial risk. Thin 5.0% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
GRFS carries more volatility with a beta of 1.19 — expect wider price swings.
GRFS is growing revenue faster at 4.0% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRFS scores higher overall (71/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Grifols SA ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?